Some examples of drugs whose development is based on targeting trafficking of misfolded, mutant GPCRs in endocrine diseases include small molecules designed for rescuing function of the V2R, MC4R, GnRHR, and more recently gonadotropin receptors (169–171). Here, LGR6 is linked to endocrine system disorder.